Cathie Wood’s Innovation ETF is up more than 30% in November, on pace for its best month ever

Investing News

Cathie Wood, CEO of Ark Invest, speaks during an interview on CNBC on the floor of the New York Stock Exchange on Feb. 27, 2023.
Brendan McDermid | Reuters

Cathie Wood is about to notch her best month ever as her holdings of innovative technology stocks roared back from steep losses in the midst of declining Treasury yields in November.

Wood’s flagship Ark Innovation ETF (ARKK) has rallied 32% this month, on pace to score its strongest month ever since its inception in 2014. The fund rebounded dramatically from three straight months of losses, pushing 2023 gains to 48%.

Stock Chart IconStock chart icon

Ark Innovation ETF

Driving the innovation fund higher this month have been biotech names Crispr Therapeutics and Twist Bioscience, along with Roku, Coinbase, Block and Shopify, which are all up at least 50%.

Despite the stellar performance this year, ARKK has suffered about $664 million in outflows in 2023, according to FactSet. Because of ARKK’s big losses over the past two years (down 67% in 2022 and off by 23% in 2021), many of the fund’s more recent investors are likely to remain hugely underwater. It closed 2020 at $124.48, compared to today’s trading level around $46.

Wood has been a firm believer that many of her big holdings stand to be leading beneficiaries from the artificial intelligence boom, including Tesla, Twilio and UiPath.

The 68-year-old CEO of Ark Invest previously said she expects the economy to slow down more than the consensus, creating an ideal environment for AI-driven companies to expand as firms seek to salvage profit margins by using their products.

Articles You May Like

Hedge funds performed better under Democratic presidents than Republican ones, history shows
AI’s Dark Horse Could Become Its Crown Jewel Under Trump
Gary Gensler reviews his accomplishments, says he was ‘proud to serve’ as SEC chair
David Einhorn to speak as the priciest market in decades gets even pricier postelection
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value